Asia-Pacific Alpha-Glucosidase Inhibitors Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

Asia-Pacific Alpha-Glucosidase Inhibitors Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

The Asia-Pacific Alpha-Glucosidase Inhibitors Market is expected to register a CAGR greater than 2% over the forecast period.

People with Covid-19 had a statistically greater incidence of type 2 diabetes and other kinds of diabetes in the Asia-Pacific region. Individuals with no history of diabetes who recovered from SARS-CoV-2 infections have been reported to develop insulin resistance and reduced insulin secretion. It has been proposed that integrated rather than disease-specific methods are needed for post-Covid syndrome diagnosis and therapy.

Alpha-glucosidase inhibitors (AGIs) are a class of diabetes medications used to treat type 2 diabetes. This activity covers the indications, mechanism of action, contraindications, adverse effects, monitoring, and other critical elements needed by healthcare professionals involved in the management of type 2 diabetes mellitus and its complications. Although alpha-glucosidase inhibitors have been studied as monotherapy and as part of a combination regimen for the treatment of diabetes, they are not considered standard first-line therapy due to their low efficacy and poor tolerance. If the gastrointestinal side effects are tolerated, they may play a role as part of a combination regimen in people who consume high-carbohydrate diets and have high postprandial glucose levels.

This is driving the demand for Alpha-Glucosidase Inhibitors Market in Asia-Pacific, thereby driving the market in focus during the forecast period.​

Key Market TrendsRising Diabetes Prevalence in Asia-Pacific Region

Among the Asia-Pacific countries, Australia and China dominate around 56% of the total Asia-Pacific Insulin Infusion Pump Market. This is mainly due to the high diabetes prevalence in these countries. China records the highest healthcare expenditure in the Asia-pacific region. According to the National Bureau of Statistics of China; MOH (China) in 2020 China’s expenditure on health is Yuan 7,217.5 billion. Expenditure includes government spending, collective spending, and private out-of-pocket spending on health care. In 2020, health expenditure in China equaled about 7.1 percent of the GDP, up from 6.67 percent in the previous year. Health insurance is voluntary in China, but the share of the population being covered by basic health insurance has grown quickly in the last ten years.

In 2021, according to Diabetes Australia, “The Australian health system spends USD 2.5 billion per annum directly on diabetes”. On top of this diabetes is a leading cause of heart disease, which costs the health system more than USD 2 billion per annum, a chronic kidney disease which costs USD 1.7 billion, and stroke which costs USD 660 million.

China is Expected to Dominate the Asia-Pacific Alpha-Glucosidase Inhibitors Market.

The alpha-glucosidase inhibitors (acarbose, miglitol, and voglibose) have been extensively studied in China. Two of them, acarbose and miglitol, are commercially available in the United States. They inhibit upper gastrointestinal enzymes (alpha-glucosidases) that convert complex polysaccharide carbohydrates into monosaccharides in a dose-dependent manner when taken orally. As a result, these drugs slow dietary carbohydrate absorption; the slower rise in postprandial blood glucose concentrations may be beneficial in both type 1 and type 2 diabetes. Acarbose may also increase insulin sensitivity in older patients with type 2 diabetes, though this may be a nonspecific effect associated with improved glycemia. When used alone or in combination with other agents that do not cause hypoglycemia, alpha-glucosidase inhibitors do not cause hypoglycemia. AGIs are effective in improving the metabolic profile and potentially lowering the risk of long-term hyperglycemia complications in patients with type 2 diabetes mellitus. They can be used alone or in combination with other antihyperglycemic medications and insulin. They have no links to any serious negative consequences. This makes them especially useful for patients with renal, cardiorespiratory, or liver issues, who are at a higher risk of developing lactic acidosis and thus are not good candidates for metformin therapy. They also do not cause hypoglycemia, making them a viable alternative to sulfonylureas, which are frequently associated with hypoglycemia. Patients should be counseled on how to maintain an appropriate diet, as a high carbohydrate diet can exacerbate gastrointestinal side effects.

Owing to the aforementioned factors the market is expected to grow during the forecast period.

Competitive Landscape

The market studied is highly fragmented into many manufacturers like Bayer, SunPharma, Pfizer, and Takeda holding a presence in all regions. The Asia-Pacific contributes the highest market share in 2021, due to many generic products in the region, especially in China and India.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.